Spyre Therapeutics, Inc. (SYRE) Tops Q1 EPS by 24c

Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q1 EPS of ($0.60), $0.24 better than the analyst estimate of ($0.84).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.

You May Also Be Interested In

• Mosaic (MOS), Others Lower Following Trump Post on Potash from Belarus
• Trump: US working on massive deal with respect to the purchase of potash from Belarus
• Bank of Canada warns new US tariffs may cut Q4 growth below 1%